Neurofibromatosis Type 1 Gene Alterations Define Specific Features of a Subset of Glioblastomas

Scheer, Maximilian; Leisz, Sandra; Sorge, Eberhard; Storozhuk, Olha; Prell, Julian; Ho, Ivy; Harder, Anja

doi:10.3390/ijms23010352

Open AccessReview

Neurofibromatosis Type 1 Gene Alterations Define Specific Features of a Subset of Glioblastomas

by

Maximilian Scheer

^1,†

,

Sandra Leisz

^1,†

,

Eberhard Sorge

²,

Olha Storozhuk

²,

Julian Prell

¹,

Ivy Ho

³

and

Anja Harder

^2,4,5,*

¹

Department of Neurosurgery, Medical Faculty, Martin Luther University Halle-Wittenberg, Ernst-Grube-Straße 40, 06120 Halle, Germany

²

Department of Neuropathology, Institute of Pathology, Medical Faculty, Martin Luther University Halle-Wittenberg, Magdeburger Str. 14, 06112 Halle, Germany

³

Department of Research, National Neuroscience Institute, Singapore 308433, Singapore

⁴

Institute of Neuropathology, University Hospital Münster, 48149 Münster, Germany

⁵

Brandenburg Medical School Theodor Fontane, Faculty of Health Sciences, Joint Faculty of the Brandenburg University, 16816 Neuruppin, Germany

^*

Author to whom correspondence should be addressed.

^†

These authors contributed equally to this work.

Int. J. Mol. Sci. 2022, 23(1), 352; https://doi.org/10.3390/ijms23010352

Submission received: 25 October 2021 / Revised: 14 December 2021 / Accepted: 24 December 2021 / Published: 29 December 2021

(This article belongs to the Special Issue Glioblastoma: Recapitulating the Key Breakthroughs and Future Perspective)

Download

Browse Figures

Review Reports Versions Notes

Abstract

Neurofibromatosis type 1 (NF1) gene mutations or alterations occur within neurofibromatosis type 1 as well as in many different malignant tumours on the somatic level. In glioblastoma, NF1 loss of function plays a major role in inducing the mesenchymal (MES) subtype and, therefore defining the most aggressive glioblastoma. This is associated with an immune signature and mediated via the NF1–MAPK–FOSL1 axis. Specifically, increased invasion seems to be regulated via mutations in the leucine-rich domain (LRD) of the NF1 gene product neurofibromin. Novel targets for therapy may arise from neurofibromin deficiency-associated cellular mechanisms that are summarised in this review.

Keywords: glioblastoma; neurofibromatosis; NF1; neurofibromin; mesenchymal; invasiveness; LRD domain

Share and Cite

MDPI and ACS Style

Scheer, M.; Leisz, S.; Sorge, E.; Storozhuk, O.; Prell, J.; Ho, I.; Harder, A. Neurofibromatosis Type 1 Gene Alterations Define Specific Features of a Subset of Glioblastomas. Int. J. Mol. Sci. 2022, 23, 352. https://doi.org/10.3390/ijms23010352

AMA Style

Scheer M, Leisz S, Sorge E, Storozhuk O, Prell J, Ho I, Harder A. Neurofibromatosis Type 1 Gene Alterations Define Specific Features of a Subset of Glioblastomas. International Journal of Molecular Sciences. 2022; 23(1):352. https://doi.org/10.3390/ijms23010352

Chicago/Turabian Style

Scheer, Maximilian, Sandra Leisz, Eberhard Sorge, Olha Storozhuk, Julian Prell, Ivy Ho, and Anja Harder. 2022. "Neurofibromatosis Type 1 Gene Alterations Define Specific Features of a Subset of Glioblastomas" International Journal of Molecular Sciences 23, no. 1: 352. https://doi.org/10.3390/ijms23010352

APA Style

Scheer, M., Leisz, S., Sorge, E., Storozhuk, O., Prell, J., Ho, I., & Harder, A. (2022). Neurofibromatosis Type 1 Gene Alterations Define Specific Features of a Subset of Glioblastomas. International Journal of Molecular Sciences, 23(1), 352. https://doi.org/10.3390/ijms23010352

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Menu

Neurofibromatosis Type 1 Gene Alterations Define Specific Features of a Subset of Glioblastomas

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI